Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247453 | 1.00 | MEN1 (0.38) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL8006097 | 1.00 | MEN1 (0.38) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL7696759 | 1.00 | MEN1 (0.38) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL51018 | 0.95 | — | — | |
| SCHEMBL4257983 | 0.89 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL219996 | 0.89 | — | — | |
| SCHEMBL2899136 | 0.86 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL5105617 | 0.86 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL19136736 | 0.84 | — | — | |
| SCHEMBL3680436 | 0.83 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | ENALARE THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | claimed |
| CN-117479945-A | Large conductance potassium channel modulators, compositions thereof, methods of making and methods of using the same | 依那拉治疗股份有限公司 | 2024-01-30 | — | — | CN | claimed |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| WO-2023192602-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. (US) | 2023-10-05 | — | — | WO | claimed |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-10-05 | — | — | US | claimed |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-07-06 | — | — | US | claimed |
| US-20230140606-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC. | 2023-05-04 | — | — | US | claimed |
| WO-2023067170-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | FUNDACIÓ INSTITUT DE BIOENGINYERIA DE CATALUNYA (ES) | 2023-04-27 | — | — | WO | claimed |
| US-9902871-B2 | Water-emulsifiable isocyanates for coatings having an improved gloss | BASF SE (DE) | 2018-02-27 | — | — | US | claimed |
| EP-2992028-B1 | WATER-EMULSIFIABLE ISOCYANATES FOR COATINGS HAVING AN IMPROVED GLOSS | BASF SE (DE) | 2017-10-04 | — | — | EP | claimed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | claimed |
| WO-2012074999-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | WO | claimed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | claimed |
| US-20060205912-A1 | Poly(urethane carbonate)polyols | BAYER MATERIALSCIENCE AG | 2006-09-14 | — | — | US | claimed |
| US-5952402-A | Phase change ink compositions | XEROX CORPORATION (US) | 1999-09-14 | — | — | US | claimed |
| US-5688312-A | INKS WITH COLORS AND IMIDES OR BISIMIDES, FOR ACOUSTIC INK PRINTER AND DROP EJECTOR | XEROX CORPORATION (US) | 1997-11-18 | — | — | US | claimed |
| US-5667568-A | Hot melt ink compositions | XEROX CORPORATION (US) | 1997-09-16 | — | — | US | claimed |
| US-5512401-A | MIXED WITH PIGMENT; ELECTROGRAPHY; LOW MELTING; RESOLUTION; RAPID JETTING RATES; LOW MELT FUSING; BROAD FUSING LATITUDE; DEINKING AT PH OF 8-11 | XEROX CORPORATION (US) | 1996-04-30 | — | — | US | claimed |
| EP-0429855-B1 | Hair dye composition | KAO CORP (JP) | 1994-09-14 | — | — | EP | claimed |
| US-4216116-A | FOR UNVULCANIZED POLYMERS | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1980-08-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | MTNR1B, CHRM3, ADRA2C | MEN1 2860/4885KMT2A 1945/4885TSHR 1976/4885 |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | PER2, SMPD4, NDUFB5 | MEN1 2898/4885KMT2A 3102/4885TSHR 3789/4885 |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ADRA2C, MTNR1B, MTNR1A | MEN1 4161/4885KMT2A 2558/4885TSHR 1302/4885 |
| US-20230140606-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | OPRK1, OPRM1, OPRD1 | MEN1 4868/4885KMT2A 1896/4885TSHR 1902/4885 |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | KCNN2, KCNN1, KCNN3 | MEN1 3506/4885KMT2A 1267/4885TSHR 3264/4885 |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ADRA2C, ADRA1B, CHRM3 | MEN1 3116/4885KMT2A 1852/4885TSHR 1042/4885 |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | SDHA, NDUFB7, OTC | MEN1 2667/4885KMT2A 2683/4885TSHR 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.